T1	p 81 130	children and adolescents with autistic disorder .
T2	p 282 332	children and adolescents with autistic disorders .
T3	p 415 450	( 5-17 years of age , who completed
T4	p 539 550	risperidone
T5	p 634 641	20 to <
T6	p 685 689	? 45
T7	p 805 814	Fifty-six
T8	p 828 865	of 79 enrolled patients completed the
T9	p 1177 1204	respiratory tract infection
T10	p 2015 2037	autistic , psychiatric
T11	p 2055 2066	disorders .
T12	i 66 77	risperidone
T13	i 220 231	risperidone
T14	i 369 391	open-label extension (
T15	i 539 550	risperidone
T16	i 724 735	risperidone
T17	i 1584 1595	risperidone
T18	i 1820 1841	risperidone treatment
T19	i 1852 1864	weight-based
T20	i 1873 1899	1.25 mg/day or 1.75 mg/day
T21	i 2000 2011	risperidone
T22	o 43 62	safety and efficacy
T23	o 187 203	long-term safety
T24	o 208 216	efficacy
T25	o 244 278	irritability and related behaviors
T26	o 565 573	weight .
T27	o 739 756	safety ; efficacy
T28	o 795 796	.
T29	o 953 974	adverse events ( AE )
T30	o 1044 1049	) AEs
T31	o 1055 1073	increased appetite
T32	o 1103 1122	weight and vomiting
T33	o 1146 1204	sedation , pyrexia , and upper respiratory tract infection
T34	o 1228 1243	nasopharyngitis
T35	o 1262 1288	and somnolence and fatigue
T36	o 1312 1330	Extrapyramidal AEs
T37	o 1381 1392	mean weight
T38	o 1409 1424	body mass index
T39	o 1490 1498	increase
T40	o 1517 1564	prolactin-related AE ( irregular menstruation )
T41	o 1629 1674	mean improvement in sleep visual analog scale
T42	o 1715 1751	improvement in efficacy scale scores
T43	o 1799 1805	safety
T44	o 1948 1953	phase
T45	o 2024 2039	, psychiatric ,
T46	o 2104 2115	improvement
T47	o 2119 2153	irritability and related behaviors